Alpha 2.0
Login Register
» Articles » PMID: 28489481

Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2017 May 11
PMID 28489481
Citations 7
Authors
Michael C Davis
Brian J Miller
Jasmeet K Kalsi
Thomas Birkner
Mitchell V Mathis
Affiliations
Soon will be listed here.
Citing Articles

Drug inhibition and substrate transport mechanisms of human VMAT2.

Wei F, Liu H, Zhang W, Wang J, Zhang Y Nat Commun. 2025; 16(1):323.

PMID: 39747030 PMC: 11695631. DOI: 10.1038/s41467-024-55361-0.

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.

Pidathala S, Liao S, Dai Y, Li X, Long C, Chang C Nature. 2023; 623(7989):1086-1092.

PMID: 37914936 DOI: 10.1038/s41586-023-06727-9.

Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).

Horiguchi J, Watanabe K, Kondo K, Iwatake A, Sakamoto H, Susuta Y Psychiatry Clin Neurosci. 2022; 76(11):560-569.

PMID: 36114799 PMC: 9826124. DOI: 10.1111/pcn.13455.

Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.

Lanfranconi S, Scola E, Bertani G, Zarino B, Pallini R, dAlessandris G Trials. 2020; 21(1):401.

PMID: 32398113 PMC: 7218540. DOI: 10.1186/s13063-020-4202-x.

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Estevez-Fraga C, Zeun P, Lopez-Sendon Moreno J Drugs Aging. 2018; 35(11):959-971.

PMID: 30357723 DOI: 10.1007/s40266-018-0590-y.